Evotec Stock Forecast
NASDAQ: EVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 9:45 AM ET
EVO analyst consensus
Consensus (3 analysts)
none
Avg. price target
$4.16+165.81%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Evotec (2026-10-08), 2 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $4.16, with a high estimate of $6.66 and a low estimate of $1.94. The average target implies upside of 165.8% from the current price of $1.57.
The spread between the highest and lowest targets is 243.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for EVO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 33% |
| Buy | 1 | 33% |
| Hold | 1 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.94 | +23.96% |
| Average target | $4.16 | +165.81% |
| High target | $6.66 | +325.56% |